Piramal Pharma Balance Sheet Health
Financial Health criteria checks 3/6
Piramal Pharma has a total shareholder equity of ₹79.1B and total debt of ₹47.1B, which brings its debt-to-equity ratio to 59.5%. Its total assets and total liabilities are ₹153.1B and ₹74.0B respectively. Piramal Pharma's EBIT is ₹5.2B making its interest coverage ratio 1.2. It has cash and short-term investments of ₹5.0B.
Key information
59.5%
Debt to equity ratio
₹47.10b
Debt
| Interest coverage ratio | 1.2x |
| Cash | ₹5.02b |
| Equity | ₹79.11b |
| Total liabilities | ₹74.00b |
| Total assets | ₹153.12b |
Recent financial health updates
Recent updates
Here's Why Piramal Pharma (NSE:PPLPHARMA) Has A Meaningful Debt Burden
Jul 14
Estimating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Jun 17We Think That There Are Issues Underlying Piramal Pharma's (NSE:PPLPHARMA) Earnings
May 21It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)
Mar 26Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Feb 28Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161
Feb 02Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Nov 09Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Aug 11Financial Position Analysis
Short Term Liabilities: PPLPHARMA's short term assets (₹54.6B) exceed its short term liabilities (₹43.7B).
Long Term Liabilities: PPLPHARMA's short term assets (₹54.6B) exceed its long term liabilities (₹30.3B).
Debt to Equity History and Analysis
Debt Level: PPLPHARMA's net debt to equity ratio (53.2%) is considered high.
Reducing Debt: Insufficient data to determine if PPLPHARMA's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: PPLPHARMA's debt is well covered by operating cash flow (21.3%).
Interest Coverage: PPLPHARMA's interest payments on its debt are not well covered by EBIT (1.2x coverage).